GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Top Cited Papers
Open Access
- 1 February 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (2) , 256-258
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved by the US Food and Drug Administration for treating type 2 diabetes (T2D). GLP-1RAs have pleiotropic effects on lowering plasma glucose, inducing weight loss, and modulating immune functions.1 Because overweight/obesity is a major risk factor for colorectal cancer (CRC),2 we hypothesize that GLP-1RAs are associated with a decreased risk for CRC in patients with T2D compared with non–GLP-1RA antidiabetics. We conducted a nationwide, retrospective cohort study among drug-naive patients with T2D comparing GLP-1RAs with 7 non–GLP-1RA antidiabetics, including metformin and insulin, which are suggested to influence CRC risk.3Keywords
This publication has 4 references indexed in Scilit:
- Time Trend and Association of Early-Onset Colorectal Cancer with Diverticular Disease in the United States: 2010–2021Cancers, 2022
- The anti-inflammatory and immunological properties of GLP-1 Receptor AgonistsPharmacological Research, 2022
- Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021JAMA Oncology, 2022
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia, 2009